Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

NCT01241682 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Malignant (Pleural) Mesothelioma

Interventions

BIOLOGICAL: DC + CTX

Sponsor

Erasmus Medical Center